Luye Pharma Group Ltd. (HKG: 2186)

Market Cap	11.29B
Revenue (ttm)	6.78B
Net Income (ttm)	827.86M
Shares Out	3.76B
EPS (ttm)	0.22
PE Ratio	13.63
Forward PE	12.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,416,000
Open	2.980
Previous Close	3.050
Day's Range	2.970 - 3.010
52-Week Range	2.340 - 4.000
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Luye Pharma Group

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,270
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2186

Financial Performance

In 2023, Luye Pharma Group's revenue was 6.14 billion, an increase of 2.70% compared to the previous year's 5.98 billion. Earnings were 532.61 million, a decrease of -11.94%.

Financial numbers in CNY